Agios Pharmaceuticals Inc. (AGIO), pioneering therapies for rare diseases, has a couple of clinical trial catalysts to watch this year.
The company's flagship drug is Mitapivat, approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency in the U.S., EU and Great Britain, under the brand name Pyrukynd.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com